Financial Toxicity in Cancer Care

As modern oncology treatments become more precise and effective, cancer care is also becoming increasingly difficult for many patients to afford. The financial burden—often referred to by experts as “financial toxicity”—extends far beyond dollars and cents, directly impacting patient treatment adherence and overall survival rates.

In an interview with Medscape following the ASTRO 2026 Annual Meeting, Dr. Fumiko Chino from MD Anderson Cancer Center highlighted how out-of-pocket costs function as a severe medical side effect.

Key Insights on Financial Toxicity

Bullet Direct Impact on Survival: Studies show that severe financial distress can lead patients to skip necessary medications, delay scans, or forego specialty care. In fact, patients facing severe bankruptcy after a diagnosis show significantly higher mortality risks.

Bullet Prevalence Across Patients: Financial distress affects one-third to one-half of cancer patients. While lower-income individuals and younger patients are at higher risk, prolonged treatments mean almost anyone can experience financial strain over time.

Bullet Overcoming Barriers to Communication: Patients often hesitate to discuss financial concerns with their care team out of fear it might affect the quality of their treatment. Experts strongly advocate for universal financial toxicity screening.

Solutions and Interventions

Addressing financial toxicity requires a multi-tiered approach:

Bullet Interpersonal: Open, structured conversations between clinicians and patients to normalize cost discussions.

Bullet Institutional: Implementing dedicated financial navigators and social workers within cancer centers to help patients access assistance programs for medication, transport, and basic needs.

Bullet Policy Level: Expanding broader social support networks to alleviate everyday financial strain, enabling patients to prioritize essential health screenings and ongoing care.

Source: Medscape